More African nations are expected to approve the malaria vaccine.

Published Date: 25 Apr 2023

With 20 million doses of a new malaria vaccine on the market for them to purchase this year, African nations are lining up to approve it.

Read Full News

Latest News



Todays Updates


NeuroVoices: Robert Alexander, MD, on the Evolution of Antiamyloid Therapeutics in Alzheimer Disease Robert Alexander, MD, Isabella Ciccone, MPH


At CTAD 2025, the chief scientific officer at the Banner Alzheimer’s Institute discussed emerging antiamyloid therapies, clinical trial insights, and treatment duration in Alzheimer disease.

Neflamapimod Reduces Plasma GFAP in Dementia With Lewy Bodies, Showing Correlation With Clinical Improvement Marco Meglio


New data highlights neflamapimod's potential in reducing biomarkers and improving clinical outcomes for dementia with Lewy bodies, paving the way for Phase 3 trials.

CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease Marco Meglio


Semaglutide shows no significant impact on Alzheimer disease progression in large trials, despite some biomarker improvements and consistent safety profiles.

New Clarity AD Analysis Reveal How Lecanemab Engages and Clears Neurotoxic Protofibrils in Alzheimer Disease Isabella Ciccone, MPH


In a study presented at CTAD 2025, patients treated with lecanemab showed a 59% increase in cerebrospinal fluid protofibril concentration at 12 months and a 45% increase at 18 months.

Autologous Stem Cell Approach Shows Promising Early Phase 1 Data in Alzheimer Disease Marco Meglio


A groundbreaking phase 1 trial reveals promising results for a new stem cell therapy targeting Alzheimer disease, advancing to phase 2 studies.

PROTECT: Sparsentan Offers CV Protection Benefits as First-Line Therapy in IgAN Chee Kay Cheung, MBChB, PhD


Recurrent UTIs Linked to QOL Burden in Kidney Transplant Recipients


Recurrent UTIs Linked to QOL Burden in Kidney Transplant Recipients

Todays Updates


NeuroVoices: Robert Alexander, MD, on the Evolution of Antiamyloid Therapeutics in Alzheimer Disease Robert Alexander, MD, Isabella Ciccone, MPH


At CTAD 2025, the chief scientific officer at the Banner Alzheimer’s Institute discussed emerging antiamyloid therapies, clinical trial insights, and treatment duration in Alzheimer disease.

Neflamapimod Reduces Plasma GFAP in Dementia With Lewy Bodies, Showing Correlation With Clinical Improvement Marco Meglio


New data highlights neflamapimod's potential in reducing biomarkers and improving clinical outcomes for dementia with Lewy bodies, paving the way for Phase 3 trials.

CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease Marco Meglio


Semaglutide shows no significant impact on Alzheimer disease progression in large trials, despite some biomarker improvements and consistent safety profiles.

New Clarity AD Analysis Reveal How Lecanemab Engages and Clears Neurotoxic Protofibrils in Alzheimer Disease Isabella Ciccone, MPH


In a study presented at CTAD 2025, patients treated with lecanemab showed a 59% increase in cerebrospinal fluid protofibril concentration at 12 months and a 45% increase at 18 months.

Autologous Stem Cell Approach Shows Promising Early Phase 1 Data in Alzheimer Disease Marco Meglio


A groundbreaking phase 1 trial reveals promising results for a new stem cell therapy targeting Alzheimer disease, advancing to phase 2 studies.

PROTECT: Sparsentan Offers CV Protection Benefits as First-Line Therapy in IgAN Chee Kay Cheung, MBChB, PhD


Recurrent UTIs Linked to QOL Burden in Kidney Transplant Recipients


Recurrent UTIs Linked to QOL Burden in Kidney Transplant Recipients

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Addition of regional nodal irradiation does not decrease rates of invasive breast cancer recurrence, study finds

2.

Increased anti-tumor response and reduced side effects from immune checkpoint inhibitors.

3.

UK study evaluates effectiveness of cancer diagnosis pathway for patients with non-specific symptoms

4.

New PET tracer enables same-day imaging of triple-negative breast and urothelial cancers

5.

First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot